Robotic assisted radical cystectomy: insights on long term oncological outcomes from the International Robotic Cystectomy Consortium by Sighinolfi, Maria Chiara et al.
  Transl Androl Urol 2019;8(Suppl 5):S521-S523 | http://dx.doi.org/10.21037/tau.2019.12.05© Translational Andrology and Urology. All rights reserved.
The goal of minimally invasive surgery in the field of 
bladder cancer (BCa) is to overcome the complexity of 
the open approach, to minimize surgical morbidity and 
to improve recovery. Apart from a brief phase attempting 
a pure laparoscopic approach, the steep and exhaustive 
learning curve (LC) and the difficulty of radical cystectomy 
(RC) made the trend rapingly moving toward the robotic 
assistance (1). The introduction of robotic assisted radical 
cystectomy (RARC) was initially slow, but afterwards 
it steadily increased both in USA and in Europe (1). 
In 12 tertiary referral centers—whose experience has 
been collected in a multicenter collaboration study from 
Zamboni et al.—the frequency of RARC has overcome the 
one of open RC in the 2015–2018 period (54% vs. 46%, 
respectively) (1). Notwithstanding some differences—such 
as major use of neobladder in European countries—the 
global tendency is similar, with blood loss and length of 
hospital stay favoring the robotic approach (2,3). Apart from 
short-term benefits of RARC, some previous oncological 
concerns—as spread and dissemination of neoplastic cells, 
atypical sites of recurrence—have been limiting some 
surgeons technically willing to afford the shift toward 
robotics for RC. The article from Hussein et al. finally 
addresses the issue of RARC safety, providing the largest 
series ever published on oncological outcomes evaluated 
10 years after surgery (4).
Data were retrieved from the International Robotic 
Cystectomy Consortium (IRCC) dataset; IRCC was 
founded in 2006 and consists of a mixture of academic and 
private centers, who joined their RARC results in a pooled 
database enrolling cases since 2003. The aim was to create 
a collaborative venture to better understand the insights of 
the new operative modality (5). 
A total of 446 patients who underwent RARC up to 2009 
were considered from IRCC database (4). Despite the very 
beginning of the robotic era, the case series seems not to be 
biased by patients’ selection, since locally advanced diseases 
(≥ pT3) finally accounted for 43%, with overall nodal 
involvement in 24%. Most of the cases were performed 
with an extracorporeal diversion, reflecting an initial cohort; 
thought, some of the more recent series or RCTs—as the 
RAZOR one (2)—still continue to rely on an extracorporeal 
approach too, possibly limiting the advantages of RARC in 
the perioperative setting.
From their initial IRCC dataset, Hussein et al. (4) 
analyzed major oncological endpoints at 10 years—
specifically recurrence free (RFS), disease-specific (DSS) 
and overall survival (OS)—and found 59% of RFS, 65% 
of DSS and 35% of OS. As stated, they appeared similar 
to the ones reported historically for open surgery. Overall, 
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44% of patients had their relapse within the 5-year period, 
consistent with the finding that most BCa recurrences 
manifest within first years after surgery. Local recurrences 
were reported in 15% of patients, extra-pelvic nodal in 5%, 
abdominal wall metastasis and peritoneal carcinomatosis in 
2.4%. No port-site recurrences were noted. To summarize, 
long-term data seem to support the introduction of RARC, 
which should be regarded as a safe procedure with enduring 
oncological results. 
Nevertheless, this initial series may suffer from a 
selection bias—not involving patients’—but surgeons’ 
selection. Even if IRCC aimed to depict RARC during 
its evolution and technical standardization (5), it should 
be kept in mind that most of the centers already had high 
volumes and previous laparoscopic and/or robotic expertise. 
Before entering IRCC trial and database, more than a third 
of surgeons have performed ≥20 RARC (6). An interim 
IRCC analysis published in 2010 highlighted that more 
than 80% of RARC before 2009 have been performed by 
surgeons already skilled in robotic radical prostatectomy 
(>50 cases) (7). Whether the burden of—and how—a 
previous RALP series may endorse RARC is unclear, but 
we have to acknowledge that many IRCC surgeons were 
already accustomed to robotic approach to the pelvis and to 
principles of laparoscopy and/or robotics. 
Such a comment arises from two matters: first, the 
positive margin rate at soft specimen is 7%, fairly low 
especially if related to the high rate of locally advanced 
disease (43% ≥ pT3) (4); second, the routinely use of pelvic 
lymphadenectomy (PLND) was not so common at that 
time, thus indicating the compliance to good oncological 
practice with adequate surgical skills among IRCC 
surgeons (6). A study from Hellenthal et al. found that 
PLND was accomplished only in 30–40% of RC by the 
end of the previous decade (8). The same author in 2010—
in a paper on PLND in the initial IRCC series—stated 
that “participating (IRCC) surgeons have some impetus to 
improve individual outcomes” and performed interventions 
at their best (6). This evidence may definitely result in 
short-term (PSM) and mid-term (RFS) excellent results 
from the initial IRCC team, resembling the ones reached 
from RCTs and bigger series a decade afterwards. 
Margin status and nodal yield—from the surgeons’ 
perspective—are surrogates of good surgical quality for 
most of the oncological procedures. But a PSM, especially 
in the field of BCa, is also a surrogate of adverse oncological 
course, as it affects local recurrence, it doubles the 
metastatic progression risk, and it impairs cancer specific 
survival (9-11). 
As expected, also in the current IRCC series, PSM is 
related to RFS. Remarkably, biological behavior of pT2 and 
of non-muscle invasive BCa is similar in terms of RFS and 
DSS, suggesting low or absent PSMs for organ-confined 
disease (4). The chance to have also a locally advanced 
disease completely and radically removed could translate 
into a better RFS, DSS and overall oncological endpoints 
improved. 
Advancement and aggressiveness of BCa—i.e., high pT, 
lymphovascular and nodal invasion - have been invoked 
as main drivers of adverse prognosis in both clinical and 
experimental settings (12,13). The recent article by Wei 
et al. (12) raises the concerns of residual cancer cells 
persisting in washing specimen after RARC; the way these 
cells are spread into peritoneum is still uncertain, but cancer 
aggressiveness seems to be the main driver of this kind of 
microscopical persistence (12,14). 
Biological behavior of transitional cell carcinoma is far 
to be defined: in this uncertain setting, the basic rules of 
surgical oncology—complete removal of the specimen 
when affordable—together with principles restored for 
laparoscopy (15)—namely a proper manipulation of 
the cystectomy specimen, the avoidance of inadvertent 
dissection into bladder or nodes, the avoidance of breach 
of the specimen bag, together with a careful prevention of 
urinary spillage from the ureters or urethral stump—still 
continue to be crucial.
What lesson can be learned from the paper by Hussein 
et al. (4)? Perioperative and oncological outcomes from 
the IRCC are actually reproducible and transferrable 
elsewhere? On one hand, the paper ensures urologists about 
a feasible, fast and safe transition from open to robotic RC; 
but, on the other, surgeons’ volume and a high-level robotic 
expertise seems to be of paramount importance to address 
the complexity of RARC and to control the aggressiveness 
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